Sign up
Log in
MARKET
NVRO
NVRO
Nevro Corp
NYSE
9.74
-0.14
-1.42%
After Hours: 9.74 +0.01 +0.10% 16:01 07/26 EDT
OPEN
10.14
PREV CLOSE
9.88
HIGH
10.14
LOW
9.62
VOLUME
445.63K
TURNOVER
0
52 WEEK HIGH
25.45
52 WEEK LOW
7.46
MARKET CAP
357.74M
P/E (TTM)
-4.2676
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NVRO last week (0715-0719)?
Weekly Report · 4d ago
Med-tech and healthcare stocks with upside during 2Q earnings - Baird
Baird analysts outlined stocks within medical technology where they see an upside during the second quarter’s earnings. Healthcare and med-tech has underperformed the broader market year-to-date. Med-tech was up 3.4% and the U.S. Health care sector was up 8.8%.
Seeking Alpha · 07/18 15:34
Nevro Is Maintained at Hold by Truist Securities
Dow Jones · 07/16 14:03
Nevro Price Target Cut to $10.00/Share From $11.00 by Truist Securities
Dow Jones · 07/16 14:03
Truist Securities Maintains Hold on Nevro, Lowers Price Target to $10
Benzinga · 07/16 13:53
Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?
Nevro Corp. (NYSE:NVRO) has US$214.8m of debt, but has more cash than debt on its balance sheet. The company has a net cash position of US$66.7m, and is in a good position to pay off its debt. Nevro has a history of losing money, and has a high debt to equity ratio. We've identified 2 warning signs with Nevro, and are looking at how risky it is.
Simply Wall St · 07/16 13:16
Beyond The Numbers: 6 Analysts Discuss Nevro Stock
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform. The company has an average price target of $10.37 for the next 12 months. 6 analysts have shared their insights on Nevro in the last three months.
Benzinga · 07/15 20:00
Nevro Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 07/15 17:19
About NVRO
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Webull offers Nevro Corp stock information, including NYSE: NVRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading NVRO stock methods without spending real money on the virtual paper trading platform.